Achilles Therapeutics announced it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019. Prior to joining Achilles, she was Vice President, Business Development for the Immuno-inflammation Therapy Area at GlaxoSmithKline where she led more than 20 transactions encompassing discovery collaborations, new company creation, M&A and late-stage product partnering deals.